Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Context: Metformin is used in pregnancy in women with gestational diabetes mellitus, polycystic ovary syndrome (PCOS), and obesity. Metformin passes the placenta. Objective: To explore the effects of metformin use in PCOS pregnancies on offspring growth to 4 years of age. Design: Follow-up study of two randomized, double-blind, placebo-controlled trials. Setting: Secondary care centers. Eleven public hospitals in Norway. Participants: One hundred eighty-two children of mothers with PCOS who participated in two randomized controlled trials. Intervention: Metformin 1700 or 2000 mg/d or placebo from first trimester to delivery in the original studies. No intervention in the current study. Main Outcome Measures: Height, weight, body mass index (BMI), and overweight/obesity at 4 years of age and head circumference at 1 year of age, converted to z scores. Results: The difference in height z score means between the groups at 4 years of age was nonsignificant (0.07 [95% confidence interval (CI): -0.22 to 0.36]; P = 0.651). At 4 years of age, the metformin group had higher weight z score than the placebo group [difference in means: 0.38 (0.07 to 0.69); P = 0.017] and higher BMI z score [difference in means: 0.45 (0.11 to 0.78); P = 0.010]. There were more overweight/obese children in the metformin group [26 (32%)] than in the placebo group [14 (18%)] at 4 years of age [odds ratio: 2.17 (1.04 to 4.61); P = 0.038]. The difference in mean head circumference z score at 1 year of age was 0.27 (-0.04 to 0.58; P = 0.093). Conclusion: Metformin-exposed children had higher BMI and increased prevalence of overweight/obesity at 4 years of age.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In one RCT of metformin use in pregnancy for polycystic ovary syndrome, follow-up of 4-year-old offspring demonstrated higher BMI and increased obesity in the offspring exposed to metformin (87).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [87]
In the citing paper
“Notably, 2 studies reported that metformin-exposed children of mothers with polycystic ovary syndrome or GDM were found to weigh more at 471 and 9 years of age.72”
From Gestational Diabetes Mellitus (2019) · cites this paper as [71]
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Extended international (IOTF) body mass index cut‐offs for thinness, overweight and obesity
Cole, T. J., & Lobstein, T. (2012) · Pediatric Obesity · doi:10.1111/j.2047-6310.2012.00064.x · Cited by 3,117
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463
Predicting adult obesity from childhood obesity: a systematic review and meta‐analysis
Simmonds, M., Llewellyn, A., Owen, C. G., & Woolacott, N. (2016) · Obesity Reviews · doi:10.1111/obr.12334 · Cited by 2,103
Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E., & Yildiz, B. O. (2016) · Human Reproduction · doi:10.1093/humrep/dew218 · Cited by 1,526
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291
Childhood obesity as a predictor of morbidity in adulthood: a systematic review and meta‐analysis
Llewellyn, A., Simmonds, M., Owen, C. G., & Woolacott, N. (2016) · Obesity Reviews · doi:10.1111/obr.12316 · Cited by 818
Pregnancy complications in women with polycystic ovary syndrome
Palomba, S., de Wilde, M. A., Falbo, A., Koster, M. P. H., La Sala, G. B., & Fauser, B. C. J. M. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv029 · Cited by 691
Cited by
McIntyre, H. D., Catalano, P., Zhang, C., Desoye, G., Mathiesen, E. R., & Damm, P. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0098-8 · Cited by 1,850
A Clinical Update on Gestational Diabetes Mellitus
Sweeting, A., Wong, J., Murphy, H. R., & Ross, G. P. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac003 · Cited by 928
15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s014 · Cited by 381
Szmuilowicz, E. D., Josefson, J. L., & Metzger, B. E. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.05.001 · Cited by 364
Sex and gender differences in developmental programming of metabolism
Dearden, L., Bouret, S. G., & Ozanne, S. E. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.04.007 · Cited by 345
“However, a recent study has shown that metformin prescribed for use during pregnancies complicated by polycystic ovary syndrome causes increased BMI in children at 4 years of age [167], showing that the use of metformin during pregnancy needs to also be carefully considered.”
Background15. Management of Diabetes in Pregnancy:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s015 · Cited by 284
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s014 · Cited by 268
14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s014 · Cited by 265
“Further study of longterm outcomes in the offspring is needed (53,54).”
Background15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s015 · Cited by 252
Tarry-Adkins, J. L., Aiken, C. E., & Ozanne, S. E. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002848 · Cited by 251
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s015 · Cited by 232
Løvvik, T. S., Carlsen, S. M., Salvesen, Ø., Steffensen, B., Bixo, M., Gómez-Real, F., Lønnebotn, M., Hestvold, K. V., Zabielska, R., Hirschberg, A. L., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30002-6 · Cited by 176
Self-citationManagement of Preexisting Diabetes in Pregnancy: A Review
Alexopoulos, A.-S., Blair, R., & Peters, A. L. (2019) · JAMA · doi:10.1001/jama.2019.4981 · Cited by 174
Recent advances in the understanding and management of polycystic ovary syndrome
Rocha, A. L., Oliveira, F. R., Azevedo, R. C., Silva, V. A., Peres, T. M., Candido, A. L., Gomes, K. B., & Reis, F. M. (2019) · F1000Research · doi:10.12688/f1000research.15318.1 · Cited by 142
Hanem, L. G. E., Salvesen, Ø., Juliusson, P. B., Carlsen, S. M., Nossum, M. C. F., Vaage, M. Ø., Ødegård, R., & Vanky, E. (2019) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30385-7 · Cited by 134
Self-citationHyperandrogenic origins of polycystic ovary syndrome-Implications for Pathophysiology and Therapy
Abbott, D. H., Dumesic, D. A., & Levine, J. E. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1576522 · Cited by 131
“In a recent long-term randomized clinical trial of daily metformin or placebo to pregnant PCOSwomen from at least 12 weeks of gestation, newborn girls exposed to metformin during gestation had increased head size [165], followed by subsequent increased adiposity and insulin resistance by ~4 years of age compared to ag…”
BackgroundImproving pregnancy outcomes in women with diabetes mellitus: modern management
Ringholm, L., Damm, P., & Mathiesen, E. R. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0197-3 · Cited by 141
Cluver, C. A., Hiscock, R. J., Decloedt, E. H., Hall, D. R., Schell, S., Mol, B. W., Brownfoot, F., Kaitu’u‐Lino, T. J., Walker, S. P., & Tong, S. (2021) · BMJ · doi:10.1136/bmj.n2103 · Cited by 139
Friedman, J. E. (2018) · Diabetes · doi:10.2337/dbi17-0011 · Cited by 119
“Indeed, metformin use in pregnancy has been challenged recently based on potential negative longer-term outcomes (142).”
BackgroundA cautionary response to SMFM statement: pharmacological treatment of gestational diabetes
Barbour, L. A., Scifres, C., Valent, A. M., Friedman, J. E., Buchanan, T. A., Coustan, D., Aagaard, K., Thornburg, K. L., Catalano, P. M., Galan, H. L., et al. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.06.013 · Cited by 101
Metformin in Reproductive Biology
Faure, M., Bertoldo, M. J., Khoueiry, R., Bongrani, A., Brion, F., Giulivi, C., Dupont, J., & Froment, P. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00675 · Cited by 109
“demonstrated that in utero exposure to metformin resulted in children with a higher body mass index (BMI) and increased prevalence of overweight/obesity at 4 years of age compared to children of the placebo group (105), indicating that in humans, metformin administered during pregnancy has the ability to alter anthrop…”
Background15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., Brown, F. M., ChallaSivaKanaka, S., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s015 · Cited by 169
Ala, M., & Ala, M. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00167 · Cited by 95
Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study
Brand, K. M. G., Saarelainen, L., Sõnajalg, J., Boutmy, E., Foch, C., Vääräsmäki, M., Morin-Papunen, L. C., Schlachter, J., CLUE Study Group, Hakkarainen, K. M., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002363 · Cited by 97
Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study
Du, Y., Zhu, Y., Zhou, Y., Ding, J., & Liu, J. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00108-w · Cited by 96
ADIPS 2020 guideline for pre‐existing diabetes and pregnancy
Rudland, V. L., Price, S., Hughes, R. C. E., Barrett, H. L., Lagstrom, J., Porter, C., Britten, F. L., Glastras, S. J., Fulcher, I., Wein, P., et al. (2020) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.13265 · Cited by 87
Gestationsdiabetes (GDM) (Update 2019)
Kautzky‐Willer, A., Harreiter, J., Winhofer-Stöckl, Y., Bancher‐Todesca, D., Berger, A., Repa, A., Lechleitner, M., & Weitgasser, R. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-018-1419-8 · Cited by 96
Gestationsdiabetes (GDM) (Update 2023)
Kautzky‐Willer, A., Winhofer, Y., Kiss, H., Falcone, V., Berger, A., Lechleitner, M., Weitgasser, R., & Harreiter, J. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02181-9 · Cited by 113
“Eine weitere Studie bei Nachkommen von Müttern, die bei PCOS 1700–2000mg Metformin in der Schwangerschaft erhielten, konnte 4 Jahre nach Entbindung ein deutlich erhöhtes Risiko für Übergewicht und Adipositas im Vergleich zur Placebogruppe feststellen [44].”
BackgroundMetformin from mother to unborn child-are there unwarranted effects?
Nguyen, L., Chan, S.-Y., & Teo, A. K. K. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.047 · Cited by 67
“The children exposed to metformin prenatally were found to have higher BMI and higher prevalence of obesity at 4 years of age even though factors such as baseline maternal characteristics at the point of inclusion,maternalweight gain, pregnancy complications and, duration of breast feeding were comparable [71].”
ResultGestational diabetes: Implications for fetal growth, intervention timing, and treatment options
Mirabelli, M., CHIEFARI, E. D., Tocci, V., Greco, E. A., FOTI, D. P., & Brunetti, A. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.06.003 · Cited by 75
Polycystic Ovary Syndrome: Challenges and Possible Solutions
Che, Y., Yu, J., Li, Y., Zhu, Y., & Tao, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041500 · Cited by 87
“[62,63] reported the PedMet-study, which is the longest follow-up study on the offspring of PCOS patients who have taken metformin during pregnancy.”
Saadati, S., Mason, T., Godini, R., Vanky, E., Teede, H. J., & Mousa, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16422 · Cited by 117
Self-citationFacchinetti, F., Appetecchia, M., Aragona, C., Bevilacqua, A., Bezerra Espinola, M. S., Bizzarri, M., D’Anna, R., Dewailly, D., Diamanti-Kandarakis, E., Hernández Marín, I., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1737675 · Cited by 63
Screening and Management of Gestational Diabetes Mellitus after Bariatric Surgery
Benhalima, K., Minschart, C., Ceulemans, D., Bogaerts, A., der Schueren, B. V., Mathieu, C., & Devlieger, R. (2018) · Nutrients · doi:10.3390/nu10101479 · Cited by 72
“Moreover, there is a paucity of long-term follow-up data on children exposed to oral agents in utero and recent data suggest that exposure to metformin in utero might significantly increase the risk for overweight and obesity in 4-year offspring [64].”
BackgroundAntidiabetic medication use during pregnancy: an international utilization study
Cesta, C. E., Cohen, J. M., Pazzagli, L., Bateman, B. T., Bröms, G., Einarsdóttir, K., Furu, K., Havard, A., Heino, A., Hernández–Díaz, S., et al. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000759 · Cited by 65
Current and experimental drug therapy for the treatment of polycystic ovarian syndrome
Corte, L. D., Foreste, V., Barra, F., Gustavino, C., Alessandri, F., Centurioni, M. G., Ferrero, S., Bifulco, G., & Giampaolino, P. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1781815 · Cited by 71
Síndrome de ovario poliquístico en la mujer adulta
Ortiz-Flores, A. E., Luque‐Ramírez, M., & Escobar-Morreale, H. F. (2019) · Medicina Clínica · doi:10.1016/j.medcli.2018.11.019 · Cited by 77
van Weelden, W., Wekker, V., de Wit, L., Limpens, J., Nikkinen, H., Leemhuis, A. G., Roseboom, T. J., van Rijn, B. B., DeVries, J. H., & Painter, R. C. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0479-0 · Cited by 57
Fornes, R., Simin, J., Nguyen, M. H., Cruz, G., Crisosto, N., van der Schaaf, M., Engstrand, L., & Brusselaers, N. (2022) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-022-00905-6 · Cited by 44
“Interestingly, we found an association between maternal metformin consumption in women without PCOS and obesity during childhood, but not in women with PCOS, as it was previously shown in studies in women with PCOS or gestational diabetes [11, 22, 52].”
BackgroundResultEfficacy and safety of metformin during pregnancy: an update
Paschou, S. Α., Shalit, A., Gerontiti, E., Athanasiadou, K. I., Kalampokas, T., Ψαλτοπούλου, Θ., Lambrinoudaki, I. V., Anastasiou, E., Wolffenbuttel, B. H. R., & Goulis, D. G. (2023) · Endocrine · doi:10.1007/s12020-023-03550-0 · Cited by 60
“Adjustment for pre-pregnancy maternal BMI did not alter the results [59].”
ResultMetformin for pregnancy and beyond: the pros and cons
Newman, C., & Dunne, F. (2021) · Diabetic Medicine · doi:10.1111/dme.14700 · Cited by 48
Vanky, E., Hanem, L. G. E., & Abbott, D. H. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.03.015 · Cited by 48
Self-citationMetformin for gestational diabetes mellitus: progeny, perspective, and a personalized approach
Barbour, L. A., & Feig, D. S. (2019) · Diabetes Care · doi:10.2337/dci18-0055 · Cited by 44
Cognitive function in metformin exposed children, born to mothers with PCOS – follow-up of an RCT
Greger, H. K., Hanem, L. G. E., Østgård, H. F., & Vanky, E. (2020) · BMC Pediatrics · doi:10.1186/s12887-020-1960-2 · Cited by 46
Self-citationSkrypnik, D., Bogdański, P., Zawiejska, A., & Wender-Ożegowska, E. (2019) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.4426 · Cited by 59
Polycystic Ovary Syndrome: Impact of Lipotoxicity on Metabolic and Reproductive Health
Brennan, K. M., Kroener, L. L., Chazenbalk, G. D., & Dumesic, D. A. (2019) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000661 · Cited by 48
Echiburú, B., Milagro, F. I., Crisosto, N., Pérez‐Bravo, F., Flores, C., Arpón, A., Salas‐Pérez, F., Recabarren, S. E., Sir‐Petermann, T., & Maliqueo, M. A. (2020) · Epigenetics · doi:10.1080/15592294.2020.1754674 · Cited by 51
“We observed that sons of women with PCOS treated with metformin gained more weight from birth until 3 months old, which is consistent with previous observations that have shown an increase in BMI and in the prevalence of overweight or obesity in prepubertal PCOS sons exposed to metformin during pregnancy, (4–7 years o…”
ResultMetformin during Pregnancy: Effects on Offspring Development and Metabolic Function
Jorquera, G., Echiburú, B., Crisosto, N., Sotomayor‐Zárate, R., Maliqueo, M. A., & Cruz, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00653 · Cited by 49
Abbott, D. H., Rogers, J., Dumesic, D. A., & Levine, J. E. (2019) · Medical Sciences · doi:10.3390/medsci7120107 · Cited by 46
Hyperandrogenism and Polycystic ovary syndrome: Effects in pregnancy and offspring development
Abruzzese, G. A., Silva, A. F., Velázquez, M. E., Ferrer, M., & Motta, A. B. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1558 · Cited by 51
Polycystic ovary syndrome in adult women
Ortiz-Flores, A. E., Luque‐Ramírez, M., & Escobar-Morreale, H. F. (2019) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.02.019 · Cited by 46
Hufnagel, A., Fernandez‐Twinn, D. S., Blackmore, H. L., Ashmore, T. J., Heaton, R. A., Jenkins, B., Koulman, A., Hargreaves, I. P., Aiken, C., & Ozanne, S. E. (2021) · The Journal of Physiology · doi:10.1113/jp281902 · Cited by 69
Diagnosis and follow-up of type 2 diabetes in women with PCOS: a role for OGTT?
Andersen, M., & Glintborg, D. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0237 · Cited by 41
Xie, Y., Xiao, L. Y., & Li, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.701590 · Cited by 39
“org 9 patients with PCOS increased the risk of later overweight in offspring at the age of 4 years compared with placebo-exposed children (34); however, the clinical implications, body composition, and metabolic health of the children in their study were unknown.”
BackgroundNicholas, L. M., & Ozanne, S. E. (2019) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2018.0116 · Cited by 38
Silverii, G. A. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15749 · Cited by 33
“…in the 9-year-old offspring of mothers with gestational diabetes in comparison with insulin, 110 and in the 4-year-old offspring of women with polycystic ovarian syndrome in comparison with placebo, 111 whereas no difference was found in the 2-year-old offspring of a mother with type 2 diabetes.”
Metformin use in obese mothers is associated with improved cardiovascular profile in the offspring
Παναγιωτοπούλου, Ό., Syngelaki, A., Georgiopoulos, G. A., Simpson, J. M., Akolekar, R., Shehata, H. A., Nicolaides, K. H., & Charakida, M. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.01.054 · Cited by 34
Schoonejans, J. M., Blackmore, H. L., Ashmore, T. J., Aiken, C., Fernandez‐Twinn, D. S., & Ozanne, S. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158104 · Cited by 39
“Moreover, further follow‐up of offspring born to metformin‐treated PCOS women up to 10 years of age showed increased overweight and obesity [12,13], with an increased proportion of metabolically abnormal obese children in the metformin arm.”
BackgroundA PCOS Paradox: Does Inositol Therapy Find a Rationale in All the Different Phenotypes?
Unfer, V., Dinicola, S., & Russo, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076213 · Cited by 34
“However, a metformin-based clinical approach is not free of concerns, including its lack of efficacy or specificity in some patients, side effects observed in long-term treatments, and the safety of its administration during pregnancy [34,35].”
BackgroundObesity and abnormal glucose tolerance in the offspring of mothers with diabetes
Kawasaki, M., Arata, N., & Ogawa, Y. (2018) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000479 · Cited by 28
Dearden, L., & Ozanne, S. E. (2023) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2022.0222 · Cited by 27
Sciacca, L., Bianchi, C., Burlina, S., Formoso, G., Manicardi, E., Sculli, M. A., & Resi, V. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02137-5 · Cited by 28
Zhu, D., Chen, Y., Huang, J., Deng, H., Shen, X., Lu, D., & Xu, L. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-909 · Cited by 28
Xu, Q., & Xie, Q. (2019) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-019-05124-w · Cited by 29
Effects of hypoxia on uteroplacental and fetoplacental vascular function during pregnancy
Arenas, G. A., & Lorca, R. A. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1490154 · Cited by 27
Wang, Y., Zeng, Z., Zhao, S., Tang, L., Yan, J., Li, N., Zou, L., Fan, X., Xu, C., Huang, J., et al. (2021) · Endocrinology · doi:10.1210/endocr/bqab056 · Cited by 24
Cao, Q., Hu, Y., Fu, J., Huang, X., Wu, L., Zhang, J., & Huang, W. (2021) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15044 · Cited by 26
“RCT follow-up of PCOS women using metformin during pregnancy also showed greater BMI of offspring at the age of 4–10.(40,41) We still need to carefully balance the potential benefits of metformin in reducing pregnancy complications and its long-term effects on offspring.”
BackgroundFeig, D. S. (2022) · Diabetes Care · doi:10.2337/dci21-0027 · Cited by 25
Garbarino, V. R., Santos, T. A., Nelson, A. R., Zhang, W. Q., Smolik, C. M., Javors, M. A., Daws, L. C., & Gould, G. G. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.013 · Cited by 24
“Another found metformin-exposed PCOS children were overweight relative to untreated PCOS controls [41].”
Effects of metformin treatment on pregnancy outcomes in patients with polycystic ovary syndrome
Raperport, C., Chronopoulou, E., & Homburg, R. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1889366 · Cited by 26
Metformin Disrupts Signaling and Metabolism in Fetal Hepatocytes
Swenson, K. S., Wang, D., Jones, A. K., Nash, M. J., O’Rourke, R., Takahashi, D. L., Kievit, P., Hennebold, J. D., Aagaard, K. M., Friedman, J. E., et al. (2023) · Diabetes · doi:10.2337/db23-0089 · Cited by 23
Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes
Ortiz-Flores, A. E., Luque‐Ramírez, M., & Escobar-Morreale, H. F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1528231 · Cited by 23
“recently associated to an increased risk of overweight in the offspring [74].”
BackgroundHanem, L. G. E., Salvesen, Ø. O., Madsen, A., Sagen, J. V., Mellgren, G., Júlíusson, P. B., Carlsen, S. M., Vanky, E., & Ødegård, R. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257186 · Cited by 20
Self-citationMetformin derivatives – Researchers’ friends or foes?
Torunoglu, S. T., Zajda, A., Tampio, J., Markowicz-Piasecka, M., & Huttunen, K. M. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115743 · Cited by 23
do Nascimento, I. B., Dienstmann, G., de Souza, M. L. R., Fleig, R., Hoffmann, C. B. P. C., & Silva, J. C. (2018) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1055/s-0038-1675214 · Cited by 21
Maternal Metformin Treatment Improves Developmental and Metabolic Traits of IUGR Fetuses
García-Contreras, C., Vázquez-Gómez, M., Pacheco, J. L. P., Torres-Rovira, L., Heras-Molina, A., Encinas, T., Astiz, S., & Gonzalez‐Bulnes, A. (2019) · Biomolecules · doi:10.3390/biom9050166 · Cited by 20
“children [38,39] as well as the negative consequences on sociability [40] and reproductive function [41] in metformin-exposed rodents.”
BackgroundLin, S., Chang, S., Kuo, C., Lin, W., Chiou, M., & Huang, Y. (2020) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-020-03207-0 · Cited by 18
In Utero Exposure to Metformin Reduces the Fertility of Male Offspring in Adulthood
Faure, M., Khoueiry, R., Quanico, J. P., Acloque, H., Guerquin, M.-J., Bertoldo, M. J., Chevaleyre, C., Ramé, C., Fournier, I., Salzet, M., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.750145 · Cited by 18
“…trials performed on the offspring of human mothers treated with metformin for PCOS during pregnancy showed that the offspring had an increase in obesity frequency and BMI (7, 30 – 34), indicating potential consequences on cardiometabolic health (7) in metformin-exposed children during adulthood.”
BackgroundBolte, E., Dean, T. A., Garcia, B. T., Seferovic, M. D., Sauter, K. A. D., Hummel, G. L., Bucher, M., Li, F., Hicks, J. M., Qin, X., et al. (2024) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2024.06.002 · Cited by 21
Management of Women with Polycystic Ovary Syndrome During Pregnancy
Valent, A. M., & Barbour, L. A. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.10.005 · Cited by 17
Deussen, A. R., Louise, J., & Dodd, J. M. (2022) · Pediatric Obesity · doi:10.1111/ijpo.12974 · Cited by 16
“Children born to women who participated in the PREGMET Study were followed up at six months, four years, and five to 10 years of age.(26,27) At all-time points assessed, children exposed in-utero to metformin had higher BMI z-scores compared with children born to women who received placebo.”
ResultLonger-term outcomes in offspring of GDM mothers treated with metformin versus insulin
Zhen, X. M., Li, X., & Chen, C. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.07.002 · Cited by 17
Helal, K. F., Badr, M. S., Rafeek, M. E.-S., Elnagar, W. M., & Lashin, M. E.-B. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-019-05430-3 · Cited by 17
Song, L., Cui, J., Hu, S., Wang, R., Li, H., & Sun, B. (2022) · Nutrients · doi:10.3390/nu14173612 · Cited by 15
“In human studies, MT treatment for GDM [11,14] or polycystic ovary syndrome (PCOS) pregnancies [15,16] was associated with increased childhood adiposity.”
BackgroundMetformin Perturbs Pancreatic Differentiation From Human Embryonic Stem Cells
Nguyen, L. T. V., Lim, L. Y., Ding, S. S. L., Amirruddin, N. S., Hoon, S. S., Chan, S., & Teo, A. K. K. (2021) · Diabetes · doi:10.2337/db20-0722 · Cited by 17
Screening and management of major endocrinopathies during pregnancy: an update
Paschou, S. Α., Bletsa, E., Papazisi, M., Mili, N., Kanouta, F., Kassi, G., Ψαλτοπούλου, Θ., Goulis, D. G., & Lambrinoudaki, I. V. (2022) · Endocrine · doi:10.1007/s12020-022-03237-y · Cited by 14
Fu, J. M., Tabbara, N., TOMLINSON, G. A., Murphy, K. E., Hamilton, J. K., & Feig, D. S. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-088653 · Cited by 15
Meng, Y., Xiang, R., Yan, H., Zhou, Y., Hu, Y., Yang, J., Zhou, Y., & Cui, Q. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15472 · Cited by 14
Cardiovascular disease risk in offspring of polycystic ovary syndrome
Shawky, N. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.977819 · Cited by 15
“On the contrary, a follow-up study on two randomized controlled trials showed that metformin-exposed children had higher BMI and increased prevalence of overweight/obesity at 4 years of age (91).”
BackgroundDrugs to Control Diabetes During Pregnancy
Feghali, M. N., Umans, J. G., & Catalano, P. M. (2019) · Clinics in Perinatology · doi:10.1016/j.clp.2019.02.005 · Cited by 16
Pharmacotherapy for hyperglycemia in pregnancy – Do oral agents have a place?
Corcoy, R., Balsells, M., García‐Patterson, A., Shmueli, A., & Hadar, E. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.04.015 · Cited by 13
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond
Newman, C., Rabbitt, L., Ero, A., & Dunne, F. (2023) · Drugs · doi:10.1007/s40265-023-01899-0 · Cited by 14
Mayadunne, T., Saadati, S., Asmelash, D., Mason, T., Vanky, E., Teede, H. J., & Mousa, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16418 · Cited by 17
“84 However, analysis of a subset of pilot data ( n = 25) showed no differences in height, weight, or body composition between children exposed to metformin in utero and those exposed to placebo when assessed between the ages of 7 and 9.”
Self-citationA Review on the Use of Metformin in Pregnancy and Its Associated Fetal Outcomes
Verma, V., & Mehendale, A. M. (2022) · Cureus · doi:10.7759/cureus.30039 · Cited by 12
Zhang, F., Ying, L., Zhang, Q., Wang, F., & Qu, F. (2022) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-021-02378-9 · Cited by 11
“The children with prenatal exposure to metformin were heavier at infancy and childhood [33, 34].”
BackgroundAntidiabetic drug metformin affects the developmental competence of cleavage-stage embryos
Nayak, G., Salian, S. R., Agarwal, P., Poojary, P. S., Rao, A. C., Kumari, S., Kalthur, S. G., Shreya, A. B., Mutalik, S., Adiga, S. K., et al. (2020) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-020-01709-6 · Cited by 11
Belva, F., Roelants, M., Vermaning, S., Desmyttere, S., Schepper, J. D., Bonduelle, M., Tournaye, H. J., Hes, F. J., & Vos, M. D. (2019) · Human Reproduction Open · doi:10.1093/hropen/hoz043 · Cited by 12
“…remains unclear (Sir-Petermann et al., 2007, 2009; Kent et al., 2008; Recabarren et al., 2008; Battaglia et al., 2009; Maliqueo et al., 2009; Hanem et al., 2018; Vanky et al., 2019), but it certainly calls for follow-up, especially because waist circumference is a widely accepted measure of…”
BackgroundSelf-citationGarcía-Contreras, C., Vázquez-Gómez, M., Pacheco, J. L. P., Heras-Molina, A., Encinas, T., Astiz, S., & Gonzalez‐Bulnes, A. (2020) · Pharmaceuticals · doi:10.3390/ph13110363 · Cited by 10
“future cognitive and mental traits, since head and brain size are positively related to better cognitive function [22,23].”
BackgroundDevelopmental effects of in utero metformin exposure.
Carroll, D. T., Sassin, A. M., Aagaard, K. M., & GANNON, M. A. (2021) · PubMed · Cited by 13
Metadata
- Authors
- Hanem, L. G. E., Stridsklev, S., Júlíusson, P. B., Salvesen, Ø., Roelants, M., Carlsen, S. M., Ødegård, R., & Vanky, E.
- Affiliations
- Norwegian University of Science and Technology (NO)
- University of Bergen (NO)
- KU Leuven (BE)
- Corresponding author
- Hanem, Liv Guro Engen
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-02-27
- Volume
- 103
- Issue
- 4
- Pages
- 1612-1621
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2790276328
- Cited by
- 199
- References
- 41
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 15 · 2023: 21 · 2022: 26 · 2021: 23 · 2020: 23 · 2019: 32 · 2018: 26
- FWCI
- 29.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Norges Forskningsråd (239987)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Birth, Development, and Health
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- metformin, polycystic ovary syndrome, pregnancy, childhood obesity, body mass index, head circumference, maternal-fetal drug transfer, prenatal drug exposure, child growth
- MeSH terms
- Child, Preschool, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Metformin, Polycystic Ovary Syndrome, Pregnancy, Pregnancy Complications, Prenatal Exposure Delayed Effects, Risk, Body Mass Index, Prevalence, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.